Brief: Scilex Holding Co Announces Final Results For Sp-102 Semdexa Efficacy And Safety From Phase 3 Trial

Sorrento Therapeutics

18/03/2022 13:31

March 18 (Reuters) - Vickers Vantage Corp I  VCKA.O :
    * SCILEX HOLDING COMPANY, A MAJORITY-OWNED SUBSIDIARY OF
SORRENTO
THERAPEUTICS, INC., ANNOUNCES FINAL RESULTS FOR SP-102
(SEMDEXA™) EFFICACY AND SAFETY FROM ITS PIVOTAL PHASE 3 CLINICAL
TRIAL PROGRAM FOR SCIATICA PAIN MANAGEMENT SUPPORTING THE
POTENTIAL FOR FIRST TO MARKET OPPORTUNITY
    * SCILEX HOLDING COMPANY - ANNOUNCED SIGNIFICANT POSITIVE
FINAL
RESULTS FROM ITS SP-102 PHASE 3 PIVOTAL TRIAL C.L.E.A.R. PROGRAM
    * SCILEX HOLDING CO - SP-102 (SEMDEXA™) SHOWED CONTINUED
REDUCTION
OF PAIN BEYOND ONE MONTH, AND MEDIAN TIME TO OPEN-LABEL REPEAT
INJECTION WAS 99 DAYS
    * SCILEX HOLDING CO - INTENDS TO USE RESULTS FROM THIS
PIVOTAL
PHASE 3 TRIAL TO DISCUSS WITH FDA IN 2022

Source text for Eikon:  ID:nGNXbPMgqY 
Further company coverage:  VCKA.O 

 ((reuters.briefs@thomsonreuters.com;))